Oncology Institute, Inc. (TOI) EBIT Margin (2021 - 2026)
Oncology Institute's (TOI) quarterly EBIT Margin came in at 4.42% in Q1 2026, up 508.0% YoY from 0.73% in Q1 2025, and up 9.21% on a QoQ basis from 4.87% in Q4 2025.
Oncology Institute, Inc. (TOI) EBIT Margin (2021 - 2026) Analysis & Trends
Oncology Institute (TOI) has 6 years of EBIT Margin data on file, last reported at 4.42% in Q1 2026.
- Quarterly EBIT Margin rose 508.0% year-over-year to 4.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.99% (up 692.0% YoY) and the FY2025 annual result came in at 7.18%, up 810.0% from the prior year.
- EBIT Margin improved to 4.42% in Q1 2026, from 4.87% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 4.42% in Q1 2026 to a low of 43.14% in Q1 2023.
- A 5-year average of 18.91% and a median of 16.97% in 2023 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 4295 bps in 2022, down 2988 bps in 2022.
- Tracing TOI's EBIT Margin over 5 years: stood at 35.11% in 2022, then jumped by 49 bps to 17.82% in 2023, then soared by 33 bps to 11.9% in 2024, then soared by 59 bps to 4.87% in 2025, then increased by 9 bps to 4.42% in 2026.
- The last three EBIT Margin figures came in at 4.42% (Q1 2026), 4.87% (Q4 2025), and 5.9% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.86% |
| Mar 31, 2026 | -4.42% |
| Dec 31, 2025 | -4.87% |
| Sep 30, 2025 | -5.90% |
| Jun 30, 2025 | -9.36% |
| Mar 31, 2025 | -9.49% |
| Dec 31, 2024 | -11.90% |
| Sep 30, 2024 | -13.87% |
| Jun 30, 2024 | -16.60% |
| Mar 31, 2024 | -18.98% |
| Dec 31, 2023 | -17.82% |
| Sep 30, 2023 | -16.97% |
| Jun 30, 2023 | -18.62% |
| Mar 31, 2023 | -43.14% |
| Dec 31, 2022 | -35.11% |
| Sep 30, 2022 | -30.93% |
| Jun 30, 2022 | -30.05% |
| Mar 31, 2022 | -33.49% |
| Dec 31, 2021 | -78.07% |
| Sep 30, 2021 | -4.13% |